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Available online 29 April 2016Transcription factors have traditionally been viewedwith skepticism as viable drug targets, but they offer the po-
tential for completely novel mechanisms of action that could more effectively address the stem cell like proper-
ties, such as self-renewal and chemo-resistance, that lead to the failure of traditional chemotherapy approaches.
Core binding factor is a heterodimeric transcription factor comprised of one of 3 RUNX proteins (RUNX1-3) and a
CBFβ binding partner. CBFβ enhances DNA binding of RUNX subunits by relieving auto-inhibition. Both RUNX1
and CBFβ are frequently mutated in human leukemia. More recently, RUNX proteins have been shown to be
key players in epithelial cancers, suggesting the targeting of this pathway could have broad utility. In order to
test this, we developed small molecules which bind to CBFβ and inhibit its binding to RUNX. Treatment with
these inhibitors reduces binding of RUNX1 to target genes, alters the expression of RUNX1 target genes, and im-
pacts cell survival and differentiation. These inhibitors show efﬁcacy against leukemia cells as well as basal-like
(triple-negative) breast cancer cells. These inhibitors provide effective tools to probe the utility of targeting
RUNX transcription factor function in other cancers.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
CBFβ
RUNX
PPI
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Triple negative breast cancer1. Introduction
Core binding factor (CBF) is a heterodimeric transcription factor
composed of a DNA-binding RUNX subunit (encoded by one of three
genes: RUNX1, RUNX2, or RUNX3) and a non-DNA-binding CBFβ subunit
which increases the afﬁnity of RUNX proteins for DNA. All three RUNX
proteins as well as CBFβ have been shown to be critical regulators of
speciﬁc developmental pathways. RUNX1 and CBFβ are essential for de-
ﬁnitive hematopoiesis, where they regulate expression of genes associ-
ated with proliferation, differentiation, and survival of stem and
progenitor cells (Friedman, 2009; de Bruijn and Speck, 2004; Wang. This is an open access article underet al., 2010; Link et al., 2010). RUNX2 is essential for normal bone forma-
tion byway of transcriptional regulation of genes critical for bone devel-
opment (Komori et al., 1997; Otto et al., 1997). Both RUNX1 and RUNX3
play key roles in neuronal development.
Perhaps not surprisingly, based on their critical roles in normal de-
velopment, RUNX proteins and CBFβ are targets of genetic alteration
in a variety of cancers. Both RUNX1 and CBFB undergo chromosomal
translocations in a subset of acute myeloid leukemia (AML) and acute
lymphocytic leukemia (ALL) patients where the corresponding fusion
proteins have clearly been shown to be drivers of disease (Blyth et al.,
2005). For the fusion proteins AML1-ETO and TEL-AML1, the binding
of the fusion proteins to CBFβ has been shown to be essential for trans-
formation (Roudaia et al., 2009). RUNX1 is also mutated in a subset of
AML and myelodysplastic syndrome (MDS) patients. In addition,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Scheitz et al., 2012; Scheitz and Tumbar, 2013). Altered expression of
RUNX2 has been implicated in breast and prostate cancers (Blyth
et al., 2005). Silencing of RUNX3 by DNA methylation has been linked
to intestinal and lung cancers (Lee et al., 2013). Due to the importance
of these proteins for normal development as well as in a variety of can-
cers, small molecules which can modulate their activity are useful tools
to address function and test new therapeutic approaches.
Small molecule inhibitors of protein-protein interactions, particular-
ly in the context of transcription factors, is still a relatively nascent ﬁeld,
in part due to the long and widely held belief that this class of interac-
tions is “undruggable”. With an increasing number of success stories
of small molecule inhibitors modulating protein-protein interactions
(Arkin et al., 2014a; Laraia et al., 2015; Arkin andWhitty, 2009), includ-
ing transcription factors, this paradigm is clearly changing. Along this
vein, we have developed tool compounds which bind to CBFβ and in-
hibit CBFβ binding to RUNX proteins as a probe for the role of this im-
portant protein-protein interaction in function as well as its potential
therapeutic applications. The most potent compounds we have devel-
oped inhibit this protein-protein interaction at lowmicromolar concen-
trations, use an allosteric mechanism to achieve inhibition, displace
CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target
genes, alter expression of RUNX1 target genes, and show clear effects
on leukemia and basal-like breast cancer cells consistent with on-
target activity on RUNX protein activity.
2. Materials and Methods
2.1. Chemical Synthesis
Details of the chemical synthesis and characterization of the com-
pounds is provided in Supplemental Information.
2.2. FRET Assays
FRET assayswere carried out as described previously (Illendula et al.,
2015; Gorczynski et al., 2007) using 100 nMCerulean-Runt domain and
100 nM Venus-CBFβ (1-141).
2.3. Pharmacokinetics Analysis of AI-12-126 and AI-14-91
Details of the pharmacokinetics analysis are provided in Supplemen-
tal Information.
2.4. GLIDE Docking
2.4.1. Ligand Preparation
Low energy 3D structures of compounds were produced using
LigPrep 2.5. Epik 2.2 was used to generate ionization/tautomeric states
of compounds. Minimum energy conformations 3 per ligand were gen-
erated using OPLS-2005 force ﬁeld.
2.4.2. Protein Preparation
The CBFβ crystal structure (PDB code 1E50)was loaded fromProtein
Data Bank and prepared using Protein Preparation Wizard. The protein
was pre-processed by assigning the bond orders, added hydrogen and
ﬁlled in the missing loops and the side chains using Prime 3.0. Waters
beyond 5 Å from hetero groups were removed, the protein is optimized
and Impref-minimization was carried using the OPLS-2005 force ﬁeld.
2.4.3. Docking
In Grid Generation, under docking tabwe have used the site as a cen-
troid of binding site residues in the protein. The active site residueswere
determined by chemical shift perturbations in 15N-1H and 13C-1H HSQC
NMR experiments of protein binding to AI-4-57. The following residues
were selected for grid generation: V86, L88, R90, E91, Y96, K98, A99,K111, G112, W113, M122, G123, C124. Docking was carried out using
the Virtual Screening Workﬂow framework. All the compounds were
docked ﬂexibly and after docking 100% of best compounds with all
good states were scored by MM-GBSA.
2.5. CBFβMutant Proteins
Wildtype CBFβ (1-141) and CBFβ (1-141) mutants R90E, K98E and
K111E were expressed at 15 °C in 15N labeled minimal media. Proteins
were puriﬁed using a Ni-NTA column, cleavedwith rTev protease diges-
tion overnight followed by size exclusion chromatography to remove
the afﬁnity tag and impurities. Protein samples at 150 μMwere dialyzed,
inserted into an NMR buffer, and titrated with 600 μM AI-4-57. All
15N-1H HSQCs were recorded on a Bruker 800 MHz NMR spectrometer
equipped with a cryoprobe.
2.6. NMR Spectroscopy
All NMR-based experimentswere acquired using CBFβ (1-141) solu-
tions in buffer containing 50 mM KPi, 0.1 mM EDTA, 1 mM DTT,
0.01%(w/v) sodium azide, 5%(v/v) DMSO and 5%(v/v) D2O at a ﬁnal
pH of 7.5. All experiments were recorded on samples of uniformly la-
beled 15N CBFβ concentrated to 0.5mMat 25 °C on a Bruker 18.8 T spec-
trometer equipped with a CryoProbe™. All NMR data were processed
using NMRPipe. Samples containing compound were made by adding
AI-4-57 in 100% DMSO to yield an equimolar protein-compound
solution.
15N and 13C chemical shift perturbationswere determined from 15N-
and 13C-HSQC experiments, respectively, collected in the presence and
absence of AI-4-57. Peaks were assigned using previously known reso-
nances, and spectra were overlaid and compared using CcpNMR soft-
ware suite (Vranken et al., 2005). Weighted chemical shift changes in
parts per million were calculated by using the equation Δ
15N + 1HN) = |ΔδHN | + (|ΔδN|/4.69) as described in Yuan et al.,
(2002). A resonance shift of 0.1 ppm or more was considered to be
signiﬁcant.
All 15N relaxation measurements were carried out with samples of
CBFβ+ AI-4-57 and CBFβ alone. 15N T1 experiments were conducted
using relaxation delays of 10, 180, 300, 500, 1300, 1800, and 2300 ms.
15N T2 experiments used relaxation delays of 10, 25, 50, 75, 100, 150,
200, 225, and 250 ms. Peak intensities were ﬁt to y = Ae−Bx, where B
is the relaxation rate (R), using CcpNMR to determine T1 and T2 relax-
ation times. R1 and R2 relaxation rates, the inverses of T1 and T2, were
used to calculate R1 ∗ R2 and R2/R1 values for protein with compound
and protein with DMSO alone. Differences in R1, R2, R1 ∗ R2 and R2/
R1 were calculated between the values for the CBFβ + AI-4-57 and
CBFβ alone samples. Residues with changes in R1 ∗ R2 greater than
two standard deviations above or below a trimmed mean consisting of
the median 60% of the data were considered signiﬁcantly different.
Saturation transfer difference NMR samples were composed of
200 μM CBFβ, 2 mM AI-4-57, 10% D2O, and 5% DMSO in 50 mM KPi,
1 mM DTT, 0.1 mM EDTA, 001% w/v NaN3, pH 7.5 in a ﬁnal volume of
200 μl. All STD experiments were performed using a 600 MHz Bruker
NMR spectrometer at 25 °C with saturation times of 500, 750, 1000,
1500, and 2000 ms. Samples were irradiated at 0.4 ppm (protein) and
30 ppm (off-resonance control) and the difference spectra calculated
using MestReNova.
2.7. Co-immunoprecipitation Assays
4 × 106 SEM cells were treated with DMSO or 10 μM of AI-4-88, AI-
10-47, AI-10-104, AI-12-126 and AI-14-91 for 6 h. Cells were lysed in
modiﬁed RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40,
0.25% sodium deoxycholate and 1 mM EDTA). RUNX1 was
immunoprecipitated from cell lysates using anti-RUNX1 antibody (Ac-
tive Motif, cat #39000,) and protein-A Agarose beads (Roche Applied
Table 1
Primers for gene expression.
Gene Forward primer Reverse primer
Runx1 GCAGGCAACGATGAAAACTA
CTC
CAAACCTGAGGTCGTTGAAT
CTC
NFE2 TCCTCAGCAGAACAGGAACAG GGCTCAAAAGATGTCTCACT
TGG
Gﬁ1 GTGAGCCTGGAGCAACACAA CTCTTGAAGCTCTTGCCACA
GA
Itga2b (CD41) AGAGGGCCATTCCTGTCTG GTCGATTCCGCTTGAAGAAG
β-2-microglobulin TTCTGGTGCTTGTCTCACTG CAGTATGTTCGGCTTCCCATTC
Spi1 (Pu.1) CCATAGCGATCACTACTGGGAT
TT
TGTGAAGTGGTTCTCAGGGA
AGT
cebpa GCAGGAGGAAGATACAGGAA
GCT
ACACCTAAGTCCCTCCCCTCTA
AA
cebpb GTTTCGGGACTTGATGCAATC CGCAGGAACATCTTTAAGTG
AT
119A. Illendula et al. / EBioMedicine 8 (2016) 117–131Science) as follows: cell lysates were mixed with protein A agarose
beads and 2 μg RUNX1 antibody in IP buffer I (50 mM Tris pH 7.5,
150 mM NaCl, 0.5% NP40, 0.25% sodium deoxycholate) and rotated at
10 rpm for 5 h. Agarose beads were washed twice with IP Buffer I
followed by washing with IP buffer II (50 mM Tris pH 7.5, 0.1% NP40,
0.05% sodium deoxycholate). All lysis, immunoprecipitation, and wash-
ing steps included DMSO/corresponding inhibitor (10 μM). The beads
were heated at 95 °C for 12 min in Western blot loading buffer
(100 mM Tris-HCL pH 6.8, 200 mM DTT, 4% SDS, 0.2% Bromophenol-
blue, 20% glycerol). The eluted protein was resolved in a 12% polyacryl-
amide gel. CBFβ was detected using anti-CBFβ antibody (provided by
Nancy A. Speck). The membrane was re-probed with anti-RUNX1 anti-
body and detected using Clean-Blot IP Detection Reagents (Thermo Sci-
entiﬁc). Relative band intensities were quantiﬁed using ImageJ
software.
2.8. Effect of CBFβ Inhibitors on RUNX1 Occupancy and Target Gene
Expression
Inducible Runx1 (iRunx) ES cellsweremaintained and differentiated
essentially as described in Lichtinger et al. (2012).
2.8.1. ES Cell Maintenance
Inducible Runx1 (iRunx) ES cells were maintained on primary
mouse embryonic ﬁbroblasts in ES maintenance media: DMEM (high
glucose from powder (Sigma D5648)), supplemented with 15% FCS,
1 mM Sodium pyruvate, 100 units/ml Penicillin and 100 μg/ml Strepto-
mycin, 1 mM glutamine, 0.15 mMMTG, 25 mMHEPES buffer, 103 U/ml
ESGRO® (Millipore), 1× non-essential amino acids (Sigma). Prior to dif-
ferentiation the ES cells were grown without feeder cells for two pas-
sages on gelatinised tissue culture treated plates.
2.8.2. ES cell differentiation
A single cell suspension of ES cells was transferred into IVDmedia on
15 cm low adherence bacteriological plates (Sterilin) at a concentration
of 2.5 × 104/ml. IVD media - IMDM supplemented with 15% FCS,
100 units/ml Penicillin and 100 μg/ml Streptomycin, 1 mM glutamine,
0.15 mM MTG, 0.18 mg/ml Human transferrin (Roche 652,202) and
50 μg/ml Ascorbic acid. After 3.25 days the embryoid bodies were col-
lected, brieﬂy digested in Tryple Express (Life Technologies) and gently
dissociated. To obtain a single cell suspension the cells were passed
through a cell strainer and resuspended in IMDM + 20% FCS.
Flk1+ve (CD309) cellswere isolated using a biotinylated Flk1 antibody
(eBioscience 13-5821) at 5 μl per 107 cells for 15min on ice, followed by
2× wash with MACS buffer (PBS + 5% BSA and 2 mM EDTA). Cells
bound by the antibody were then isolated using MACS anti-biotin
beads and MACS LS columns (Miltenyi Biotec) according to the
manufacturer's instructions. Isolated Flk1 + ve cells were plated in
Blast media at a concentration of 9 × 103/cm2 on gelatinized tissue cul-
ture treated dishes. Blast media–IMDM supplemented with 10% FCS,
100 units/ml Penicillin and 100 μg/ml Streptomycin, 1 mM glutamine,
0.45 mMMTG, 0.18 mg/ml Human transferrin, 25 μg/ml Ascorbic acid,
20% D4T conditioned media, 5 μg/l mVEGF (Peprotech), 10 μg/l mIL-6
(Miltenyi Biotec). After approximately 40 h in blast culture, iRunx was
induced by the addition of 0.1 μg/ml doxycycline (dox). At the same
time as dox induction, the indicated concentrations of AI-14-91 or the
control compound AI-4-88 were added. Adherent cells were washed
and harvested by trypsinisation 24h later and used for either FACS anal-
ysis, protein extract preparation, resuspended in TRIzol (Life Technolo-
gies) for RNA isolation or crosslinked for chromatin isolation.
2.8.3. mRNA expression analysis
RNA was extracted from cells using TRIzol® (Life Technologies) ac-
cording to the manufacturer's instructions. DNase treatment was per-
formed using Turbo DNase (Ambion) according to manufacturer's
instructions and a further clean up step was performed usingNucleoSpin RNA columns (Macherey Nagel). First strand cDNA synthe-
sis was carried out using Superscript II (Life Technologies) according to
manufacturer's instructions using 250 ng of RNA. Real Time PCR was
carried out using ABI SYBR® green master mix with 2.5 μl of diluted
cDNA and 0.25 μMprimer per 10 μl reaction on anABI 7900HTmachine.
Analysis was carried out according to the 2−ΔΔCt method, normalizing
to GAPDH and using the +Dox sample as the calibrator, samples were
measured in duplicate. Error bars represent standard deviation where
n = 3. See Table 1 for gene expression primer sequences.
2.8.4. FACS Analysis
Surface marker expression for CD41 and KIT (CD117) was assessed
by FACS analysis using CD117-APC (BD Pharmingen 553356) and
CD41 PE-Cy7 (e-Bioscience 25-0411) antibodies.
2.8.5. Western Blotting
Whole cell extracts were run on 4–20% TGX gels (Bio-Rad) and blot-
ted using the Trans-Blot Turbo transfer system (Bio-Rad) according to
the manufacturer's instructions. Blots were blocked with 4% milk pow-
der in 0.05% TBS-Tween and incubated with anti-HA (1:1000 dilution,
H6908 Sigma), anti-CBFβ (1:400, sc20693 Santa Cruz), and anti-
GAPDH antibodies (1:8000 dilution, ab8245 Abcam). Proteins were vi-
sualized using Pierce SuperSignal West Pico Chemiluminescent sub-
strate (Thermo Scientiﬁc).
2.8.6. Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed essentially as de-
scribed previously (Lichtinger et al., 2012) with the exception that the
material was crosslinked with Di(N-succinimidyl)-glutarate (DSG;
Sigma) and 1% Formaldehyde (Thermo Fisher) before quenching with
1/10th volume 2 M glycine. Nuclei were prepared essentially as de-
scribed previously (Lefevre et al., 2003), sonicated using a Bioruptor
water bath in immunoprecipitation buffer I (25 mM Tris 1 M, pH 8.0,
150 mM NaCl, 2 mM EDTA, pH 8.0, 1% TritonX-100 and 0.25% SDS).
After centrifugation the sheared 0.5–2 kb chromatin fragments (1–
2 × 106 cells) were diluted with 2 volumes immunoprecipitation buffer
II (25 mM Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA, pH 8.0, 1% TritonX-
100, 7.5% glycerol) and precipitation was carried out for 2–3 h at 4 °C
using 2 μg anti-HA antibody (H6908) coupled to 15 μl Protein-G
dynabeads. Beads were washed with low salt buffer (20 mM Tris,
pH 8.0, 150 mM NaCl, 2 mM EDTA, pH 8.0, 1% TritonX-100, 0.1% SDS),
high salt buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 2 mM EDTA,
pH 8.0, 1% TritonX-100, 0.1% SDS), LiCl buffer (10 mM Tris, pH 8.0,
250 mM lithium chloride, 1 mM EDTA, pH 8.0, 0.5% NP40, 0.5%
sodium-deoxycholate) and TE pH 8.0 containing 50 mM sodium chlo-
ride. The immune complexes were eluted in 100 μl elution buffer
(100 mM NaHCO3, 1% SDS) and after adding 4 μl 5 M sodium chloride
and 0.5 μl proteinase K, the crosslinks were reversed at 65 °C overnight.
DNA was extracted using the Ampure PCR puriﬁcation kit (Beckman
Table 2
Primers for ChIP.
Gene Forward primer Reverse primer
Pu.1 3′ enhancer GCTGTTGGCGTTTTGCAAT GGCCGGTGCCTGAGAAA
Oct4 promoter TGGGCTGAAATACTGGGT
TC
TTGAATGTTCGTGTGCCAAT
Itga2b (CD41)
promoter
CTGTGAAAGTCCAGCCAC
CAT
AGTGAGCCAGGCAGCGAAT
NFE2 -3kb TGTTTGGCAACAATGCTT
GTG
CAACCCACCTCCACTACGTAT
Chr2 AGGGATGCCCATGCAGTCT CCTGTCATCAGTCCATTCTC
CAT
Chr1 TGCTCCACAGTGTCCATG
TACA
AGCAATTTCATGGGTGAGAG
AAG
120 A. Illendula et al. / EBioMedicine 8 (2016) 117–131Coulter) according to the manufacturer's instructions and analyzed by
qPCR. Primers used for ChIP analysis are shown in Table 2.2.9. Differentiation of HPC-7 Cells
Effects of inhibitors on HPC-7 cell differentiation was carried out as
described in Supplemental Information.2.10. Viability of a Panel of Leukemia Cell Lines and Normal CellsWith CBFβ
Inhibitors
2.10.1. Cell Lines
Leukemia cell lines were purchased either from the American Type
Culture Collection (ATCC), Dr. Chiosis Laboratory (MOLM-13, HEL and
M0-91) or Dr. Lucio's Castilla's laboratory (ME-1). All cell lines have
been authenticated. Cells were cultured in Iscove's Modiﬁed Dulbecco's
Medium (IMDM; Life Technologies) supplemented with 10% fetal bo-
vine serum (FBS) according to culture conditions indicated by ATCC
and 1% penicillin/streptomycin (Pen/Strep; Life Technologies).2.10.2. Cell Viability Assay
AML cell lineswere cultured at 5 × 105 cells/ml in 96-well plates and
treated for 48 hwith the indicated compounds at different doses orwith
DMSO. Cells were stainedwithDAPI (Life Technologies). At least 2 × 104
events for cell lines per conditionwere characterized on a BD LSR II ﬂow
cytometer. Data analysis was performed using FlowJo 9.3 software for
Mac OS X (TreeStar). Cells that were negative for DAPI were scored as
viable, and the viability was represented as the percent relative to un-
treated controls.2.10.3. Colony Assays With Normal Human Cord Blood Cells
Colony forming assay was performed as described (Guzman et al.,
2007). Brieﬂy, primary cord blood (CB) cells were obtained from the
New York Blood Bank. Mononuclear cells (MNCs) were isolated by
Ficoll. MNCs were cultured in the presence or absence of 10 μM or
20 μM of the indicated compounds for 48 h in serum free medium sup-
plemented with cytokines (Hassane et al., 2010). Cells (25,000) were
plated in MethoCult H4434 (Stemcell Technologies). Colonies were
scored after 14 days of culture.2.11. Runx1 Knockdown
Knockdown of RUNX1 (Wang et al., 2011)was determined by quan-
titative immunoblotting (Janes, 2015) with the following antibodies:
RUNX1 (Cell Signaling #4336, 1:1000), RUNX2 (MBL International
#D130-3, 1:1000), CBFβ (Santa Cruz Biotechnologies #SC-20693,
1:1000), vinculin (Millipore #05-386, 1:10,000), tubulin (Abcam
#ab89984, 1:20,000), and GAPDH (Ambion #AM4300, 1:20,000).2.12. Effects of CBFβ Inhibitors on Acini Formation in 3D Culture of
MCF10A-5E Cells and on the Viability of the Basal-like Breast Cancer Cell
Line HC1143 in 3D Culture
MCF10A-5E cells expressing shRUNX1 have been described previ-
ously (Janes et al., 2010;Wang et al., 2011). HCC1143 cells were obtain-
ed from ATCC and cultured in growth medium (RPMI + 10% FBS)
according to the provider's recommendations. For 3D culture, cells
were seeded at 5000 cells/well atop growth factor-reduced matrigel
(BD) in assay medium (MCF10A-5E) or growth medium
(HCC1143)+ 5 ng/ml EGF (Peprotech)+ 2%matrigel as described pre-
viously (Debnath et al., 2003). CBFβ inhibitors (1 μM) or 0.1% DMSO
were added at the time of plating and replenished every four days
with fresh assay or growth medium+ EGF + matrigel.
3. Results
3.1. Initial Lead for Small Molecule Inhibitors of CBFβ-RUNX BindingWhich
Bind to CBFβ
We recently reported the 2-pyridyl benzimidazole AI-4-57 as a com-
poundwhich binds to the CBFβ portion of the CBFβ-SMMHC fusion pro-
tein and inhibits its binding to the Runt domain of RUNX proteins
(Illendula et al., 2015). Using our previously described FRET assay for
binding of the amino acid 1-141 portion of CBFβ to the Runt domain
(Gorczynski et al., 2007), we showed this compound is also a modest
potency inhibitor of the binding of wildtype CBFβ to the RUNX1 Runt
domain (see Fig. 1, Table 3). In order to develop more potent analogs
for use as tool compounds to probe RUNX and CBFβ protein function,
we synthesized a library of analogs of AI-4-57 and characterized their
activity.
3.2. Identiﬁcation of Pharmacophore and Exploration of Structure-Activity
Relationships (SAR)
To get a better understanding of which functional groups of AI-4-57
are essential for its activity and to generate more effective inhibitors, a
group of analogs were synthesized. All synthesized compounds were
puriﬁed by ﬂash chromatography and characterized by NMR and mass
prior to evaluation in the FRET assay. As shown in Fig. 1b, Schemes 1–
3 we probed several regions of AI-4-57 to deﬁne a pharmacophore for
activity. Substitution of the pyridine ring with a phenyl ring (2a) or a
furan (2b, Fig. 1b, Scheme 1) resulted in a complete loss of activity (Sup-
plementary Table 1). Replacement of the methoxy functionality with a
hydrogen (AI-4-88, 3a) also resulted in complete loss of activity. Fig.
1c shows the results of STD NMR analysis (Mayer and Meyer, 1999;
Mayer and Meyer, 2001) of AI-4-57 binding to CBFβ. When short satu-
ration times are used for this experiment, it can be effectively used to
map epitopes on amolecule which are in close contact with the protein.
With a short saturation time of 500 ms, we observe the signal for the
methyl group of the methoxy functional group as well as the signal for
the neighboring 4 hydrogen of the benzimidazole ring in the difference
spectrum, consistent with this portion of the molecule being in close
contact with the protein as well as with the effect of removing this sub-
stituent on activity. We further explored the 5-position by introducing
ﬂuorine (3c), triﬂouromethyl (3f), methyl (3d), and ethoxy (3b, Fig.
1b, Scheme 2) substitutions. Introduction of triﬂuoromethyl or methyl
resulted in a loss of activity whereas introduction of ﬂuorine or ethoxy
resulted in compounds with similar activity (Supplementary Table 1).
Moving the 5-methoxy to the 4-position (4a) resulted in reduced activ-
ity (Supplementary Table 1). Methyl (4h), methoxy (4g) and ﬂuorine
(4i) substitutions ortho to the pyridine nitrogen (Fig. 1b, Scheme 3) re-
sulted in inactive compounds (Supplementary Table 1). As shown in Fig.
1c, short saturation time STD NMR identiﬁes this hydrogen as being in
close contact with the protein, providing a rationale for the loss of activ-
ity observed with substitutions at this position. This data established
Fig. 1. Identiﬁcation of pharmacophore. A. FRET assay results for AI-4-57, AI-10-104, and AI-14-91. Cerulean-Runt domain and Venus-CBFβ concentration was 100 nM. X-axis indicates
compound concentration and y-axis is ratio between the emission intensities at 525 and 474 nm. Experiments were performed in duplicate. Error bars represent average ± standard
deviation. The average data points were ﬁt using Origin. B. Schemes 1–3 illustrate the targets of modiﬁcations to AI-4-57 as well as compounds synthesized and assayed to delineate
the active pharmacophore. C. Results of STD NMR experiment with AI-4-57 (2 mM) and CBFβ (200 μM). Bottom panel shows 1D NMR spectrum of AI-4-57. Upper 2 panels show STD
difference spectra (off-resonance (70 ppm) saturation spectrum minus on-resonance (0.4 ppm) CBFβ saturation spectrum) with saturation times of 500 and 2000 ms.
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Table 3
Results of FRET assays for selected compounds. All compounds were measured in dupli-
cate. Each dataset was ﬁt to derive an IC50 value. IC50 values are reported as the average
of these two independent ﬁts ± the standard deviation.
Compound ID Structure FRET IC50 (μM)
AI-4-57 34.3 ± 0.3
AI-10-47 3.2 ± 0.5
AI-10-104
(a)
1.25 ± 0.06
AI-12-16
(b)
1.7 ± 0.2
AI-14-55
(c)
4.8 ± 0.3
AI-12-126
(d)
8.9 ± 1.3
AI-14-91
(e)
3.0 ± 0.5
AI-14-18
(h)
5.0 ± 0.3
AI-14-72
(i)
1.7 ± 0.2
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of CBFβ-Runt domain binding by this class of molecules. As shown in
Supplementary Fig. 1, we subsequently prepared a series of compounds
to further explore the SAR. FRET assay inhibition data for themost active
compounds that emerged from this effort are shown in Table 3.
3.3. Inhibitors With Favorable ADMET Properties
Development of a useful tool compound which can be utilized for
in vivo studies requires optimization not only of the activity of the com-
pound but also its metabolic stability in vivo. In the context of our pre-
vious work on development of small molecule inhibitors that are
speciﬁc for CBFβ-SMMHC (Illendula et al., 2015), we showed that AI-
4-57 has a short half-life in mice with loss of the methyl group on the
methoxy functionality being the resulting metabolite. Introduction of
triﬂuoromethoxy abrogated the metabolic liability. Introduction of a
triﬂuoromethoxy substitution into AI-4-57 yielded a compound (AI-
10-47) with improved activity in the FRET assay (see Table 1) as well
as in assays of cellular activity (see below). Introduction of this substitu-
tion into 7a (Supplementary Fig. 1), yielded the inhibitor AI-10-104
with IC50 = 1.25 μM (Table 1). However, administration of AI-10-104Fig. 2.GLIDE based docking of inhibitors to CBFβ. A. Surface representation of the binding pocke
ribbon representation of the structure of CBFβ. B. Surface representation of the binding pock
positive; green, neutral) in same orientation as in A. C. Schematic showing the identity of the
(blue) with AI-4-57 bound. The sidechains of R90 and K111 are displayed and colored red. E.
for wildtype, R90E, and K111E CBFβ proteins. Resonances for CBFβ alone are in blue and thoseto mice via intraperitoneal (IP) injection of a captisol formulation at
178 mg/kg resulted in signiﬁcant sedative effects within 30 s, from
which themice recovered in approximately 1 h,whereas administration
of a nanoparticle formulation at 200mg/kg was lethal in approximately
~3.5 h. Hypothesizing that this effect is driven by an off-target activity,
we have engineered additional analogs (AI-12-126, AI-14-55, and AI-
14-91, see Table 1) where we have appendedmorpholine ring substitu-
ents to the pyridine ring, thereby altering the structure as well as polar-
ity of the compounds. These compounds retain similar activity in the
FRET assay to the parent compounds (see Table 3). Importantly, AI-
12-126 and AI-14-91, when formulated as the HCl salts with captisol
and administered IP at 100 mg/kg do not induce the sedative effects
seen with AI-10-104 and are well-tolerated by mice. Measurements of
the pharmacokinetic properties of these compounds in mice (see
Supplementary Fig. 2) showed that at a dose of 100 mg/kg, we can
achieve useful concentrations of the compounds with reasonable half-
lives in vivo (AI-14-91, oral gavage, t1/2 = 203 min). These derivatives
are, therefore, viable options for in vivo studies of CBFβ and RUNX
function.3.4. GLIDE Based Model of Inhibitor Binding to CBFβ
The structure of CBFβ was solved using NMR spectroscopy (Huang
et al., 1999) and the crystallization of this very soluble protein has not
been reported. Therefore, we have focused on using a combination of
chemical shift perturbations in the NMR spectrum of CBFβ upon AI-4-
57 binding combined with GLIDE based docking to gain insight into
the bindingmode. AI-4-57 induces chemical shift changes both in back-
bone NH resonances aswell as in the sidechain CH resonances of the ar-
omatic sidechains of Trp113 and Tyr96 in CBFβ (Illendula et al., 2015).
These chemical shift changes provide key experimental information to
identify the location of the binding site and guide docking using the pro-
gram GLIDE. Interestingly, the chemical shift perturbation data indicate
binding to a site that is spatially close to the Runt domain binding site on
CBFβ but on the opposite side of the protein, i.e. the compounds act in
an “allosteric” manner to inhibit the protein-protein interaction.
We used the residues identiﬁed as perturbed in the NMR data as
constraints to dock AI-4-57 to CBFβ using GLIDE. We obtained two dif-
ferent docking poses with similar GLIDE docking scores, with the com-
pound ﬂipped by ~180° between the two (Fig. 2, Supplementary Fig.
3). In one pose (Supplementary Fig. 3), the pyridine ring is buried
such that substitutions at the 5 position would sterically clash with
the protein whereas in the other pose this position is not obstructed
(Fig. 2). Substitutions at this position (compare for example AI-10-104
with AI-12-16 in Table 1) are well tolerated, indicating that the pose
shown in Fig. 2 is the correct one.
As shown in Fig. 2a, we see the compound binding into a relatively
shallow pocket on the surface of the protein. The model shows rotation
of the pyridine ring relative to the benzimidazole ring in the bound con-
formation, a result which is consistent with the increased activity of AI-
10-104,with a 3-methoxy substituted pyridine ringwhichwill force the
pyridine ring out of planarity with the benzimidazole, relative to AI-10-
47 (Table 3). Display of the partial charge distribution of the compounds
and the protein (Fig. 2b) shows signiﬁcant partial positive charge from
the protein interacting favorably with partial negative charge from the
compound. Fig. 2c identiﬁes all the amino acids lining the binding pock-
et for the compound. We found the GLIDE based docking and scoring is
able to distinguish inactive from active compounds, however its ability
to quantitatively distinguish among the active compounds is limited.t on CBFβ (grey) with AI-4-57 (blue) bound as determined using GLIDE, all overlayed on a
et on CBFβ with AI-4-57 bound colored according to partial charge (red, negative; blue,
residues making contact with AI-4-57. D. Ribbon representation of the structure of CBFβ
Overlays of selected regions of 15N-1H HSQC spectra of CBFβ alone and CBFβ+ AI-4-57
for CBFβ+ AI-4-57 are in red.
123A. Illendula et al. / EBioMedicine 8 (2016) 117–131In order to conﬁrm the validity of this model, we have introduced 3
mutations into CBFβ to probe their effects on compound binding:
Arg90- N Glu, Lys98- N Glu, and Lys111- N Glu. All of these residues arelocated in the binding pocket (Fig. 2d). The 15N-1HHSQCNMR spectrum
of the Lys98Glu mutant protein showed wide-scale changes indicative
of a disruption of the fold, so this mutation was not further analyzed.
124 A. Illendula et al. / EBioMedicine 8 (2016) 117–131For the Arg90- N Glu and Lys111- N Glu mutant proteins, we have com-
pared the observed chemical shift changes in an 15N-1H HSQC spectrum
upon addition of AI-4-57 compared to thewildtype protein (Fig. 2e). For
the Arg90 mutant we observe reduced chemical shift changes and for
the Lys111 mutant, there is no chemical shift change, consistent with
a loss of binding to the protein. This data experimentally validates the
site of binding and supports the accuracy of the GLIDE model.3.5. Molecular Basis for Allosteric Inhibition
As the CBFβ inhibitors bind at a site that is not on the binding inter-
face for RUNX binding on CBFβ (see Fig. 3), they act via an allosteric
mechanism. This could occur by way of structural changes induced in
the protein by compound binding and/or by alteration of the dynamics
of the protein upon compound binding. Signiﬁcant chemical shift
changes upon AI-4-57 binding are conﬁned to the binding site for the
compound (see Fig. 3). As shown in Fig. 3b and Supplementary Fig. 4,
upon binding of AI-4-57 to CBFβ we do observe small chemical shift
changes for amino acids located on the RUNX binding interface on
CBFβ. As the magnitude of these chemical shift changes is quite small,
it is clear that there is not any signiﬁcant conformational change at the
binding interface. We therefore hypothesized that there must be a
change in dynamics associatedwith compound bindingwhichmediates
the reduced afﬁnity. To test this idea, we have collected and analyzed
15N backboneR1 andR2data and calculated the difference in R1 ∗R2 be-
tween free CBFβ and CBFβ bound to AI-4-57 (Fig. 3c, Supplementary
Fig. 5). Such an R1 ∗ R2 plot readily identiﬁes residues with increased
dynamics on either the μs-ms or ps-ns timescales (Kneller et al.,
2002). Fig. 3c shows a plot of the difference between R1 ∗ R2 for
CBFβ+ AI-4-57 and CBFβ alone. In this plot, residues above zero indi-
cate increased μs-ms timescale dynamics upon compound binding and
residues below zero indicate increased ps-ns timescale dynamics upon
compound binding. Residues which displayed R1 ∗ R2 difference values
greater than two times the standard deviation from the trimmed mean
were deemed to be signiﬁcant.We observe changes in dynamics for res-
idues located in the binding site for the inhibitor, resulting from both
the binding and dissociation of compound aswell as compound induced
changes in protein dynamics (Fig. 3d). Interestingly, these changes
occur both in the μs-ms timescale dynamics (principally near the benz-
imidazole ring) as well as on the ps-ns timescale (in the vicinity of the
pyridine ring),with the latter perhaps a result of ringﬂipping of the pyr-
idine ring. Importantly, we observe signiﬁcant changes in dynamics for
residues that are located at the binding interface for RUNX binding
(Fig. 3e), including one residue that has been shown by previous muta-
genesis studies to be an important contributor to the energetics of bind-
ing. Fig. 3e highlights two of these residues, Arg131 and Asn104. For
Arg131, we observe increased μs-ms timescale dynamics with
compound binding. Arg131 is a known contact residue with the Runt
domain (Zhang et al., 2003). For Asn104, we observe an increase in
ps-ns timescale dynamics with compound binding. Strikingly, our
previous mutagenesis studies have shown that mutation of this residue
has the largest effect of any of the CBFβmutations we have character-
ized (Tang et al., 2000), i.e. Asn 104 is a hotspot residue for the binding
of CBFβ to the Runt domain. This amino acid makes multiple contactsFig. 3. Effects of CBFβ inhibitors on protein chemical shifts and backbone dynamics measure
heterodimer with a surface representation colored in red for the residues in the AI-4-57 bind
57 is that deduced from GLIDE docking. B. Structure of the CBFβ-Runt domain heterodimer w
upon AI-4-57 binding having their surface colored in red. Residues in the Runt domain wh
representations. C. Plot of the difference in the measured 15N backbone R1 ∗ R2 values betwe
with the residues in the AI-4-57 binding pocket which display changes in R1 ∗ R2 upon AI-
timescale motion are colored red and those showing increased μs-ms timescale motion are co
domain binding interface on CBFβ which show changes in R1 ∗ R2 upon AI-4-57 indicated
indicates increased μs-ms timescale motion. Residues in the Runt domain which make contac
identities of the residues involved are indicated in green for CBFβ and in magenta for the Runtwith residues in the Runt domain (Val159, Ala160, Thr161, Asp66)
and mutation to Ala results in a 21-fold reduction in binding afﬁnity
(Tang et al., 2000).3.6. Comparison to Ro5-3335
The small molecule Ro5-3335 was reported to be an inhibitor of
CBFβ/RUNX function (Cunninghamet al., 2012). This compoundwas re-
ported to have been identiﬁed based on a hit from an alpha-screen for
the CBFβ-Runt domain interaction, however the compound does not
show signiﬁcant effects in the alpha screen assay and does not show
an effect on CBFβ-RUNX1 binding in cells (Cunningham et al., 2012). It
also shows no effect on CBFβ-Runt domain binding in our FRET assay
(Supplementary Fig. 6a). We also could not detect any interaction
with either CBFβ or the RUNX1 Runt domain by NMR. The only target
identiﬁcation data presented (protein binding by UV measurement of
adherence to nickel resin bound protein) indicated it binds to both
CBFβ and RUNX1 (Cunningham et al., 2012). This seems unlikely from
a chemical perspective, so the actual target of action is unclear. As this
compound has structural similarity to known bromodomain inhibitors
(Smith et al., 2014; Gallenkamp et al., 2014), we have screened this
compound for activity against a panel of 32 bromodomains using a
commercial screen (DiscoveRx BromoScan). This screen showed
that at 1 μM, similar to the low μM concentrations where activity is
reported for this compound in cellular assays, the SMARCA2 and
WDR9(2) bromodomains were ~40% inhibited (Supplementary
Fig. 6b). SMARCA2 is a member of the SWI/SNF family of proteins. The
human SWI/SNF complex has been shown to associate with RUNX1
(Bakshi et al., 2010). In addition, SMARCA2 is listed as a common inter-
action partner of TBP andRUNX1 by theprotein-protein interaction pre-
diction program PIPS. Based on this, the lack of effect on CBFβ-RUNX
binding, and the lack of clear target validation, we would suggest that
the mechanism of action of Ro5-3335 may be based on inhibition of
SMARCA2 rather than direct inhibition of CBFβ/RUNX, unlike the inhib-
itors we are reporting herein.3.7. CBFβ Inhibitors Disrupt CBFβ-RUNX1 Binding in SEM Cells
To test whether the CBFβ inhibitors can disrupt the binding of full
length CBFβ to full length RUNX1 in cells, we performed co-
immunoprecipitation experiments in the SEM cell line. In order to
limit effects on the viability of the cells, the treatment time was limited
to 6 h. As shown in Fig. 4 (a replicate is shown in Supplementary Fig. 7;
data for AI-4-57 in Supplementary Figure 8), we see a clear reduction in
binding of CBFβ binding to RUNX1 in cells treated with 10 μM AI-10-
104, AI-12-126, and AI-14-91. As AI-10-47 showed only amodest effect,
we have measured the aqueous solubility of all 5 compounds tested in
0.25% DMSO by NMR spectroscopy, mimicking the conditions used for
the coIP. Consistent with the coIP results, AI-10-104, AI-12-126, and
AI-14-91 are signiﬁcantly more soluble than AI-10-47, explaining the
reduced activity seen for AI-10-47 in this assay. No effect was observed
on the levels of CBFβ or RUNX1upon treatmentwith inhibitors (Supple-
mentary Figure 9).d using NMR spectroscopy. A. Structure of the CBFβ (green) – Runt domain (magenta)
ing pocket which undergo chemical shift changes upon binding. The orientation of AI-4-
ith residues on the Runt domain binding interface which display chemical shift changes
ich make contact with these CBFβ residues are displayed as magenta colored surface
en CBFβ+ AI-4-57 and CBFβ alone. D. Structure of the CBFβ-Runt domain heterodimer
4-57 binding indicated as a surface representation. Residues showing increased ps-ns
lored blue. E. Structure of the CBFβ-Runt domain heterodimer with residues on the Runt
as surface representations. Red indicates increased ps-ns timescale motion and blue
t with these residues are indicated as a surface representation and colored magenta. The
domain.
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Fig. 4. CBFβ inhibitors reduce CBFβ binding to RUNX1 in cells. Co-immunoprecipitation
assays of lysates from acute myeloid leukemia SEM cells treated with AI-4-88, AI-10-47,
AI-10-104, AI-12-126 and AI-14-91 at 10 μM for 6 h. RUNX1-bound CBFβ protein levels
and immunoprecipitated RUNX1 are shown on the top panel. Quantiﬁcation of RUNX1
bound CBFβ is shown on the bottom graph. Protein levels were normalized to RUNX1
and depicted relative to DMSO control.
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Gene Expression
CBFβ increases the DNA binding activity of RUNX proteins by reliev-
ing auto-inhibition (Adya et al., 2000). Therefore, wewould predict that
inhibition of CBFβ-RUNXbindingwill reduce RUNXoccupancy on target
genes and alter their expression. As RUNX proteins are context-
dependent regulators of gene expression, this could result in increases
or decreases in concomitant gene expression depending on the target
gene. To test this, we have used an inducible iRunx ES cell system
which allows the expression of HA tagged Runx1 under the control of
a doxycycline (dox) responsive promoter in a Runx1−/− genetic back-
ground (Lichtinger et al., 2012). The cells were differentiated according
to an established model of in vitro hematopoiesis in which ES cells are
differentiated into hematopoietic progenitors (Choi et al., 1998;
Sroczynska et al., 2009). This system provides a model which makes it
possible to dissect themechanisms that drive the differentiation process
at different stages of hematopoietic development. In the absence of
Runx1, cells are unable to progress past the hemogenic endothelium
stage of development and generate hematopoietic progenitors
(Fig. 5a). By inducing Runx1 and hence the assembly of activating (or
repressive) complexes at Runx1-responsive loci its role in mediating
the endothelial to hematopoietic transition can be examined.
ES cells were differentiated as described in the methods section and
only adherent cells were harvested, since at this stage of differentiation
very few cells had progressed to free ﬂoating progenitors. To examine
the effect of CBFβ inhibition of RUNX1-dependent differentiation, we
performed FACS analysis using antibodies against KIT, a growth factorFig. 5. Effects of CBFβ inhibitors on RUNX1occupancy and target gene expression. A. Schematic d
allowed to form embryoid bodies (EB) in IVD culture media and hemangioblast Flk1 + ve cell
doxycycline (−dox) RUNX1 is absent and cells cannot progress from the HE1 stage of devel
progresses, resulting in the formation of CD41 + ve/KIT + ve progenitors. B. Representative
with the compounds and dox as indicated. The percentage of cells expressing KIT and CD41
Gene expression analysis of inhibitor treated cells using RNA prepared from cells treated with
the presence of dox. Relative expression of genes is shown, normalized to GAPDH and using
analysis of HA-Runx1 binding following Runx1 induction by dox and treatment with inhibitor
used to identify binding at selected amplicons and enrichment normalized to input and the
ANOVA test was used to analyze variance in HA enrichment values between the inhibitor an
** denotes p b 0.01. E. Representative western blots showing levels of inducible Runx1 and
inhibitor or control compound.receptor which is expressed on cells with haemopoietic potential, and
CD41, a surface marker of newly committed multipotent progenitor
cells. We found that treatment with the AI-14-91 inhibitor but not the
inactive control compound (AI-4-88) resulted in a strong decrease in
the percentage of cells expressing both these surface markers (Fig. 5b).
For gene expression analysis, we tested 4 genes that are activated by
RUNX1 (increased by Dox induction) – Nfe2, Sfpi1 (Pu.1), Itga2b (CD41)
andGﬁ1. In each case, addition of the inhibitor (AI-14-91) but not the in-
active control compound (AI-4-88) resulted in a dose dependent de-
crease in expression level (Fig. 5c).The expression level of Cebpa, an
indirect target of RUNX, was also decreased. Cebpbwhich is not a direct
Runx1 target was relatively unaffected by the inhibitor, as was β-2-
microglobulin which was used as a negative control.
To test whether the disruption of RUNX1-CBFβ interaction abrogat-
ed chromatin binding of RUNX1, chromatin from differentiating cells
was immunoprecipitated using an HA antibody which recognizes the
HA tag on the iRUNX protein and examined RUNX1 binding to several
well-known RUNX1 target regions (Fig. 5d) (Lichtinger et al., 2012).
When normalized to input and a negative control region (Chr2),
RUNX1binding is increased upon dox induction at the Sfpi1 (Pu.1) 3′ en-
hancer (−14kb 3′URE), the Itga2b (CD41) promoter, and the NFE2-3kb
enhancer-element. Bindingwas reduced in the presence of the inhibitor
(AI-14-91) but not the inactive control compound (AI-4-88). A control
region of Chr1 and the Oct4 promoter, which is not active at this stage
of differentiation, served as negative controls. Western blots demon-
strated that cells under each of the dox induced conditions expressed
comparable levels of RUNX1 and CBFβ protein (Fig. 5e).
3.9. CBFβ Inhibitors Induce Myeloid Differentiation of HPC-7 Cells
RUNX1 levels are high in hematopoietic stem cells and early
progenitors, thendecreasewith differentiation into themyeloid lineage.
We therefore hypothesized that CBFβ inhibitors would enhance differ-
entiation into the myeloid lineage under conditions where that is
preferred. To test this, we have cultured the HPC-7 cell line for 10 days
under conditions where myeloid differentiation was favored. As
shown in Supplementary Figure 10, addition of CBFβ inhibitors (AI-
10-104, AI-14-91) to the culture results in a signiﬁcant increase in
differentiation as assessed by the appearance of the macrophage-
speciﬁc surface marker CD11.
3.10. CBFβ Inhibitors Inhibit Growth of Leukemia Cell Lines
CBFβ/RUNX1 function is essential for normal hematopoiesis. Both
CBFβ and RUNX1 are targets of chromosomal translocations in human
leukemia. Recent studies showed that RUNX1 is required for the
maintenance of leukemia cells expressing AML1-ETO, MLL-AF9, as
well as T-ALL cells (Ben-Ami et al., 2013; Goyama et al., 2013;
Kwiatkowski et al., 2014). Based on these ﬁndings, we hypothesized
that CBFβ inhibitors may have utility for different types of leukemia.
We therefore screened inhibitors against a panel of 11 leukemia cell
lines with varying genotypes (see Fig. 6). We did not observe any
activity for the inactive control compound AI-4-88 and only very weak
activity for the modest potency AI-4-57. However, for all the moreiagram representing the inducible Runx1 (iRx) ES cell differentiation system. ES cellswere
s were sorted and seeded into blast culture media and cultured for 40 h. In the absence of
opment. In the presence of doxycycline (+dox) Runx1 is expressed and differentiation
FACS histograms showing staining of the surface markers CD41 and KIT in cells treated
is reduced by treatment with AI-14-91 but not with the control compound AI-4-88. C.
and without dox and cells treated with 10 μM, 20 μM and 30 μM AI-14-91 or AI-4-88 in
+dox as the calibrator. Error bars represent standard deviation where n = 3. D. ChIP
or control compound. ChIP with an anti-HA antibody recognizing HA tagged Runx1 was
Chr2 control is shown. Error bars represent standard deviation where n = 5. A one-way
d control compound, or between inhibitor and +dox treatment, * denotes p b 0.05 and
CBFβ protein in the cell populations. Where indicated, cells were treated with 20 μM
127A. Illendula et al. / EBioMedicine 8 (2016) 117–131active inhibitors tested (AI-10-47, AI-10-104, and AI-14-91) we
observed signiﬁcant growth inhibition of the majority of the cell
lines. Importantly, we observe only very modest effects, and no effectof AI-14-91 on the colony formation of normal human cord blood cells
(Supplementary Figure 11), suggesting there could be a useful thera-
peutic window.
Fig. 6. Effects of CBFβ inhibitors on the viability of a panel of leukemia cell lines. Percent viability for 11 leukemia cell lines after 48 h of treatment with the indicated compounds. The
viability is represented as the percent DAPI negative cells relative to DMSO control. Each symbol/color represents an individual cell line. The symbol represents the mean of
independent replicates and the error bars represent the S.E.M. The table indicates the morphology, type of leukemia, and known mutations for each of the 11 cell lines.
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3D Culture and Block Growth of Basal-like Breast Cancer Cells in 3D Culture
RUNX-mediated gene expression is important for normal breast ep-
ithelial biology and breast cancer (Lau et al., 2006; Pratap et al., 2006;
Pratap et al., 2009; Shore, 2005; Kadota et al., 2010; van Bragt et al.,
2014). To evaluate whether CBFβ inhibition would inﬂuence the multi-
cellular organization of basal-like breast epithelia, we used 3D culture of
MCF10A-5E cells (Janes et al., 2010). Knockdown of RUNX1 in these
cells delays proliferation arrest and promotes the formation of non-
spherical acini, indicating a role for RUNX1 during morphogenesis
(Wang et al., 2011). When shRUNX1 or control cells were cultured
with CBFβ inhibitors at 1 μM concentration, we observed a substantial
increase in the formation of multiacinar structures compared to carriercontrol or inactive compound (Fig. 7a). The extent of multiacinus
formation greatly exceeded that of RUNX1 knockdown, suggesting a
phenotypic role for other RUNX-family members such as RUNX2,
which is also expressed in these cells (Wang et al., 2011). The inhibitors
appear to be initiating a nascent branching program that is reminiscent
of when TGFβ-family signaling is impaired (Wang et al., 2014). RUNX
transcription factors are well-recognized effectors of TGFβ-family
ligands (Ito and Miyazono, 2003), which are naturally retained in the
extracellular matrix (Schneyer et al., 2008; Taipale et al., 1996).
RUNX and CBFβ mutations have been described in luminal breast
cancer (Banerji et al., 2012; Ellis et al., 2012), but the role of RUNX in
basal-like breast cancer is less clear (Janes, 2011). Increased levels of ex-
pression of RUNX1 and RUNX2 have been shown to be present in basal-
like breast cancers and to correlate with poor prognosis (McDonald
Fig. 7. Effects of CBFβ inhibitors on acini formation by MCF10A-5E cells and viability of basal-like breast cancer cell line HC1143. CBFβ inhibitors alter acinar morphogenesis of basal-like
breast epithelial cells and block survival of basal-like breast cancer cells in 3D organotypic culture. A. MCF10A-5E cells stably expressing shRUNX1 or shGFP control were grown in 3D
culture for 10–11 days with the indicated compounds at 1 μM concentration and imaged by brightﬁeld microscopy. The total number of multiacini per chamber was counted and
scaled to the shGFP DMSO control. Data are shown as the mean ± s.e.m. of eight independent cultures. Quantitative immunoblotting for RUNX1, RUNX2, CBFβ, vinculin, tubulin, and
GAPDH is shown to the right. B. HCC1143 cells were grown in 3D culture for 18 days with the indicated compounds at 1 μM concentration and imaged by brightﬁeld microscopy. The
total number of proliferating colonies per chamber was counted, and data are shown as the mean ± s.e.m. of four independent cultures. Scale bar is 200 μm.
129A. Illendula et al. / EBioMedicine 8 (2016) 117–131et al., 2014; Ferrari et al., 2014). We surveyed the Cancer Cell Line
Encyclopedia and identiﬁed HCC1143 cells as a line in the Basal A sub-
type with high expression of RUNX transcripts as measured bymicroar-
ray. When HCC1143 cells were grown under 3D culture conditions in
the presence of active CBFβ inhibitors at 1 μM concentration, weobserved a striking blockade in cell survival, with zero detectable
colonies after 18 days (Fig. 7b). These results suggest that persistent
RUNX-mediated gene expression is required in a subset of basal-like
breast cancers, opening a potential therapeutic opportunity for CBFβ
inhibitors.
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Transcription factors represent an important as well as challenging
class of proteins for the development of small molecule inhibitors.
Because of their function as crucial regulators of cell fate decisions in a
normal andmalignant context and as mediators of a wide swath of sig-
naling pathways they are particularly attractive targets for cancer ther-
apy.Moreover, it is nowabundantly clear that tumorigenesis inmultiple
tissues involves the deregulation of gene expression and a subversion of
the normal cell differentiation processes (Bonifer and Cockerill, 2011).
However, transcription factors do not act alone, but function in the con-
text of large multi-protein assemblies, which requires the targeting of
intracellular protein-protein or protein-DNA interactions. This has
proved to be more challenging than targeting enzymatic activity due
to the nature of the interaction surfaces and the complexity of the
assemblies, provoking the notion that this class of proteins is
“undruggable”. Nevertheless, efforts in a number of labs have now
demonstrated successful targeting of this class of proteins, opening up
numerous avenues for novelmodes of action to approach the treatment
of cancer. Herein, we describe the development of a small molecule in-
hibitor which targets the heterodimeric core binding factor (CBF) tran-
scription factor, speciﬁcally the protein-protein interaction between
CBFβ and RUNX, the two subunits of CBF. We have optimized the activ-
ity as well as the ADMET properties based on an initial hit to generate
tool compoundswhichwe have shownbind to CBFβ and inhibit binding
to RUNX1, resulting in decreased binding of RUNX1 to target sites in the
genome and concomitant changes in the level of expression of RUNX1
target genes. While we have only experimentally demonstrated disrup-
tion of binding with RUNX1, all three RUNX proteins are known to bind
CBFβ. In addition, the Runt domain of the RUNX proteins, towhich CBFβ
binds, is almost identical in sequence among the family members and
no differences are found on the surface of the Runt domainwhich inter-
acts with CBFβ. Based on this, it is our expectation that similar effects
will be seen for these inhibitors on CBFβ-RUNX2 and CBFβ-RUNX3
binding. As such, the biological effects observed likely reﬂect activity
against all the RUNX proteins present in a particular cell type. These
compounds meet the criteria outlined by Frye for a high quality chemi-
cal probe (Frye, 2010), including a clear molecular proﬁle of activity,
mechanism of action, identity of active species, and proven utility.
Our inhibitors act via an allostericmechanism, i.e. they donot bind at
the protein-protein interface. Such a mode of action has been seen with
numerous small molecule inhibitors of enzymes, but there have only
been limited reports of such allosteric inhibitors of protein-protein
interactions (Arkin et al., 2014b). However, this mechanism has clear
advantages as the inhibitor does not have to directly compete with
the partner protein. Our NMR relaxation data support a model for the
activity of these compounds where induction of changes in the dynam-
ics of critical hotspot binding residues on the RUNXbinding interface on
CBFβmediate loss of binding. Such a dynamics basedmechanism is con-
sistent with numerous NMR studies of allosteric communication which
have demonstrated altered dynamics as a mechanism.
The interaction between CBFβ and RUNX1 is essential for normal
hematopoiesis. The CBFβ inhibitors block the induction of RUNX1-
dependent genes during the endothelial-hematopoietic transition
(EHT) and inhibit RUNX1 binding to its target genes. Moreover, this re-
sult highlights the crucial role of not only the presence of the complete
CBF complex, but its actual binding to chromatin for the EHT. At later
differentiation stages, RUNX1 inhibition enhances myeloid differentia-
tion of the HPC-7 cell line, which is consistent with the reduction in
expression of RUNX1 that occurs upon progressing from the hemato-
poietic stem cell (HSC) to the myeloid lineage. Based on these results,
we explored the biological effects of the CBFβ inhibitors in a disease
context. Since all three RUNX proteins (RUNX1, 2, 3) bind CBFβ, the bi-
ological effects of these inhibitors likely reﬂect the inhibition of all the
RUNX proteins present in the cell lines used. We have previously
shown that this interaction is essential for the transforming propertiesof the leukemia causing fusion proteins AML1-ETO and TEL-AML1
(Roudaia et al., 2009). Our data therefore suggest a potential therapeutic
use of the CBFβ inhibitors in leukemia as they are effective in killing a
variety of different leukemia cell lines, consistent with recent results in-
dicating a critical role for both mutated and wild-type RUNX1 in such
cells (Ben-Ami et al., 2013; Goyama et al., 2013), while having minimal
impact on normal cord blood cells. However, the anti-tumor activity of
the compounds is not restricted to hematological malignancies. CBFβ
inhibitors increased multiacinar structures in breast cell 3D culture,
conﬁrming the crucial role of RUNX1 in this phenotype indicated by
previous knock-down experiments, and completely inhibited the
growth of a basal-like breast cancer cell line in 3D culture. Currently
there is no effective therapy for basal-like breast cancer, so our results
support targeting of the RUNX pathway for this very poor prognosis
cancer. Our study clearly demonstrates the utility of these compounds
for exploring the effects of CBFβ-RUNX inhibition across a broad spec-
trum of cancers.
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